The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Alzheimer’s, the most common form of dementia, is one of the leading causes of death in western countries such as the UK. But current medicines can only slightly alleviate the symptoms, of ...

A pair of FDA-approved cancer drugs may help reverse the biological changes that drive Alzheimer’s disease, according to a ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Scientists have used AI to re-analyse a clinical trial for an Alzheimer’s medicine, and identified a group of patients who responded to treatment. The work demonstrates that AI can inform the design ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers found that patients who were given the drug lecanemab in the earliest days of ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found that the drug slowed cognitive decline by 46% in a group of ...